Results from Phase III study of lumasiran in paediatric patients with primary hyperoxaluria type 1 presented at conference

In the 6-month primary analysis of the single-arm ILLUMINATE-B study, which included infants and children aged <6 years (n=18), treatment with lumasiran was associated with a 72% mean reduction in spot urinary oxalate:creatinine ratio (no absolute results reported).

Source:

Biospace Inc.